Cardio-oncology: Cardiovascular Complications of Cancer Therapy

References

• American Cancer Society . Cancer facts and figures 2015 . www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2015.html .
   Google Scholar
• Abe J , MartinJF, YehE . The future of onco-cardiology: we are not just “side effect hunters” . Circ. Res.119, 896 – 899 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Wickramasinghe CD , NguyenKL, WatsonKE, VorobiofG, YangEH . Concepts in cardio-oncology: definitions, mechanisms, diagnosis and treatment strategies of cancer therapy-induced cardiotoxicity . Future Oncol.12, 855 – 870 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Hamo C , BloomM . Getting to the heart of the matter: an overview of cardiac toxicity related to cancer therapy . Clin. Med. Insights Cardiol.9 ( S2 ), 47 – 51 ( 2015 ).
   PubMedGoogle Scholar
• Akam-Venkata J , FrancoV, LipshultzS . Late cardiotoxicity: issues for childhood cancer survivors . Curr. Treat. Options Cardiovac. Med.18 ( 7 ), 47 ( 2016 ).
   PubMedGoogle Scholar
• Shelburne N , AdhikariB, BrellJet al. Cancer treatment-related cardiotoxicity: current state of knowledge and future research priorities . J. Natl Cancer Inst.106 ( 9 ), dju232 ( 2014 ).
   PubMedGoogle Scholar
• Felker G , ThompsonR, HareJet al. Underlying long-term survival in patients with initially unexplained cardiomyopathy . N. Engl. J. Med.342, 1077 – 1084 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Bhave M , AkhterN, RosenS . Cardiovascular toxicity of biological agents for cancer therapy . Oncology28 ( 6 ), 482 – 490 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Albini A , PennesiG, DonatelliF, CammarotaR, De FloraS, NoonanD . Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention . J. Natl Cancer Inst.102 ( 1 ), 14 – 25 ( 2010 ).
   PubMedGoogle Scholar
• Curigliano G , CardinaleD, SuterTet al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines . Ann. Oncol.23 ( Suppl. 7 ), vii155 – vii166 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Zamorano J , AboyansV, AchenbachSet al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines . Eur. J. Heart Fail.19 ( 1 ), 9 – 42 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Ewer MS , LippmanSM . Type II Chemotherapy-related cardiac dysfunction: time to recognize a new entity . J. Clin. Oncol.23 ( 13 ), 2900 – 2902 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Seidman A , HudisC, PierriMKet al. Cardiac dysfunction in the trastuzumab clinical trials experience . J. Clin. Oncol.20 ( 5 ), 1215 – 1221 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Mollinaro M , AmeriP, MaroneGet al. Recent advances on pathophysiology, diagnostic and therapeutic insights in cardiac dysfunction induced by antineoplastic drugs . BioMed. Res. Int. 2015, 138148 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Herrmann J , LermanA, SandhuN, VillarragaH, KohliM . Evaluation and management of patients with heart disease and cancer: cardio-oncology . Mayo Clin. Proc.89, 1287 – 1306 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Doroshow J . Anthracycline antibiotic stimulated superoxide, hydrogen peroxide and hydroxyl radical production by NADH dehydrogenase . Cancer Res.43, 4543 – 4515 ( 1983 ).
   PubMed Web of Science ®Google Scholar
• Zhang S , LiuX, Bawa-KhalfeTet al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity . Nat. Med.18, 1639 – 1642 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Vejpongsa P , YehE . Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity . Clin. Pharmacol. Ther.95 ( 1 ), 45 – 52 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hoshino A , MitaY, OkawaYet al. Cytosolic p53 inhibits Parkin-mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart . Nat. Commun.4, 2308 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Lenneman C , SawyerD . Cardio-oncology: an update on cardiotoxicity of cancer-related treatment . Circ. Res.118 ( 6 ), 1008 – 1020 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Huang C , ZhangX, RamilJMet al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice . Circulation121 ( 5 ), 675 – 683 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• De Angelis A , PiegariE, CappettaDet al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function . Circulation121 ( 2 ), 276 – 292 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Mercurio V , PirozziF, LazzariniEet al. Models of heart failure based on the cardiotoxicity of anticancer drugs . J. Card. Fail.22 ( 6 ), 449 – 457 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Zamorano JL , LancellottiP, Rodriguez MuñozDet al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) . Eur. Heart J.37 ( 36 ), 2768 – 2801 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Swain SM , WhaleyFS, EwerMS . Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials . Cancer97 ( 11 ), 2869 – 2879 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Cardinale D , ColomboA, BacchianiGet al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy . Circulation131 ( 22 ), 1981 – 1988 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Smith L , CorneliusV, PlummerCet al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials . BMC Cancer10, 337 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Lipshultz S , AdamsM, ColanSet al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association . Circulation128 ( 17 ), 1927 – 1995 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Slamon DJ , ClackGM, WongSG, LevinWJ, UllrichA, McGuireWL . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene . Science235 ( 4785 ), 177 – 182 ( 1987 ).
   PubMed Web of Science ®Google Scholar
• Cobleigh M , VogelC, TripathyDet al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease . J. Clin. Oncol.17 ( 9 ), 2639 – 2648 ( 1999 ).
   PubMed Web of Science ®Google Scholar
• Arnould L , GellyM, Penault-LlorcaFet al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br. J. Cancer 94, 259 – 267 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Junttila TT , AkitaRW, ParsonsKet al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 . Cancer Cell15 ( 5 ), 429 – 440 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Molina MA , Codony-ServatJ, AlbanellJ, RojoF, ArribasJ, BaselgaJ . Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells . Cancer Res.61 ( 12 ), 4744 – 4749 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Baselga J . Targeting tyrosine kinases in cancer: the second wave . Science312 ( 5777 ), 1175 – 1178 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Hudis CA . Trastuzumab–mechanism of action and use in clinical practice . N. Engl. J. Med.357 ( 1 ), 39 – 51 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Negro A , BrarBK, LeeKF . Essential roles of Her2/erbB2 in cardiac development and function . Recent Prog. Horm. Res.59, 1 – 12 ( 2004 ).
   PubMedGoogle Scholar
• Ky B , VeipongsaP, YehE, ForceT, MoslehiJ . Emerging paradigms in cardiomyopathies associated with cancer therapies . Circ. Res.113 ( 6 ), 754 – 764 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Izumi Y , XuL, di TomasoE, FukumuraD, JainR . Tumour biology: herceptin acts as an anti-angiogenic cocktail . Nature416 ( 6878 ), 279 – 280 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Chavez-MacGregor M , ZhangN, BuchholzTet al. Trastuzumab-related cardiotoxicity among older patients with breast cancer . J. Clin. Oncol.31 ( 33 ), 4222 – 4228 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Sysa-Shah P , TocchettiC, GuptaMet al. Bidirectional cross-regulation between ErbB2 and β-adrenergic signaling pathways . Cardiovasc. Res.109 ( 3 ), 358 – 373 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Bowles E , WellmanR, FeigelsonHet al. Pharmacovigilance Study Team . Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study . J. Natl Cancer Inst.104 ( 17 ), 1293 – 1305 ( 2012 ).
   PubMedGoogle Scholar
• Procter M , SuterT, de AzambujaEet al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial . J. Clin. Oncol.28 ( 21 ), 3422 – 3428 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Chen J , LongJ, HurriaA, OwusuC, SteingartR, GrossC . Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer . J. Am. College Cardiol.60 ( 24 ), 2504 – 2512 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ewer M , VooletichM, DurandJet al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment . J. Clin. Oncol.23 ( 31 ), 7820 – 7826 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Yang B , PapoianT . Tyrosine kinase inhibitor (TKI)-induced cardiotoxicity: approaches to narrow the gaps between preclinical safety evaluation and clinical outcome . J. Appl. Toxicol.32 ( 12 ), 945 – 951 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Chen M , KerkeläR, ForceT . Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics . Circulation118 ( 1 ), 84 – 95 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Krause DS , Van EttenRA . Tyrosine kinases as targets for cancer therapy . N. Engl. J. Med.353 ( 2 ), 172 – 187 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Imai K , TakaokaA . Comparing antibody and small-molecule therapies for cancer . Nat. Rev. Cancer6 ( 9 ), 714 – 727 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Ghoreschi K , LaurenceA, O’SheaJJ . Selectivity and therapeutic inhibition of kinases: to be or not to be?Nat. Immunol.10 ( 4 ), 356 – 360 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Wu S , ChenJJ, KudelkaA, LuJ, ZhuX . Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis . Lancet Oncol.9 ( 2 ), 117 – 123 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Chu T , RupnickMA, KerkelaRet al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib . Lancet370 ( 9604 ), 2011 – 2019 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Richards C , JeY, SchutzFet al. Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib . J. Clin. Oncol.29 ( 25 ), 3450 – 3456 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug Administration . Sorafenib prescribing information and package insert ( 2010 ). www.accessdata.fda.gov/drugsatfda_docs/label/2010/021923s008s009lbl.pdf .
   Google Scholar
• Darby SC , EwertzM, McGalePet al. Risk of ischemic heart disease in women after radiotherapy for breast cancer . N. Engl. J. Med.368 ( 11 ), 987 – 998 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Heidenreich P , KapoorJ . Radiation induced heart disease: systemic disorders in heart disease . Heart95 ( 3 ), 252 – 258 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Gaya A , AshfordR . Cardiac complications of radiation therapy . Clin. Oncol.17 ( 3 ), 153 – 159 ( 2005 ).
   Web of Science ®Google Scholar
• Ng A . Review of the cardiac long-term effects of therapy for Hodgkin lymphoma . Br. J. Haematol.154 ( 1 ), 23 – 31 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Patnaik J , ByersT, DiGuiseppiC, DabeleaD, DenbergT . Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study . Breast Cancer Res.13 ( 3 ), R64 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Accordino M , NeugutA, HershmanD . Cardiac effects of anticancer therapy in the elderly . J. Clin. Oncol.32 ( 24 ), 2654 – 2661 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Groarke J , NguyenP, NohriaA, FerrariR, ChengS, MoslehiJ . Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease . Eur. Heart J.35 ( 10 ), 612 – 623 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Khandaker M , EspinosaR, NishimuraRet al. Pericardial disease: diagnosis and management . Mayo Clin. Proc.85 ( 6 ), 572 – 593 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ewer M , GianniL, PaneFet al. Report on the international colloquium on cardio-oncology . Ecancermedicalscience8, 433 ( 2014 ).
   PubMedGoogle Scholar
• Galper S , YuJ, MauchPet al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation . Blood117 ( 2 ), 412 – 418 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Aleman B , van den Belt-DuseboutA, De BruinMet al. Late cardiotoxicity after treatment for Hodgkin lymphoma . Blood109 ( 5 ), 1878 – 1886 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Sardaro A , PetruzzelliM, D’ErricoM, GrimaldiL, PiliG, PortaluriM . Radiation-induces cardiac damage in early left breast cancer patients: risk factors, biological mechanisms, radiobiology, and dosimetric constraints . Radiother. Oncol.103 ( 2 ), 133 – 142 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Adams MJ , HardenberghPH, ConstineLS, LipshultzSE . Radiation-associated cardiovascular disease . Crit. Rev. Oncol. Hematol.45 ( 1 ), 55 – 75 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Plana J , GalderisiM, BaracAet al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging . J. Am. Soc. Echocardiogr.27 ( 9 ), 911 – 939 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Pizzino F , VizzariG, QamarRet al. Multimodality imaging in cardiooncology . J. Oncol. 2015, 263950 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• de Geus-Oei L , Mavinkurve-GroothuisA, BellersenLet al. Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity . J. Nucl. Med. Technol.41 ( 3 ), 170 – 181 ( 2013 ).
   PubMedGoogle Scholar
• Sawaya H , SebagI, PlanaJet al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthrecyclines, taxanes and trastuzumab . Circ. Cardiovasc. Imaging5 ( 5 ), 596 – 603 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Cardinale D , SandriM, ColomboAet al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy . Circulation109 ( 22 ), 2749 – 2754 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Dodos F , HalbsguthT, ErdmannE, HoppeU . Usefulness of myocardial performance Index and biochemical markers for early detection of anthracycline-Induced cardiotoxicity in adults . Clin. Res. Cardiol.97 ( 5 ), 318 – 326 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Sandri M , SalvaticiM, CardinaleDet al. N-terminal Pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin. Chem. 51 ( 8 ), 1405 – 1410 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Romano S , FratiniS, RicevutoEet al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients . Br. J. Cancer105 ( 11 ), 1663 – 1668 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Feola M , GarroneO, OccelliMet al. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide . Int. J. Cardiol.148 ( 2 ), 194 – 198 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Jingu K , NemotoK, KanetaTet al. Temporal change in brain natriuretic peptide after radiotherapy for thoracic esophageal cancer . Int. J. Radiat. Oncol. Biol. Phys.69 ( 5 ), 1417 – 1423 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• D’Errico M , GrimaldiL, PetruzzelliMet al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer . Int. J. Radiat. Oncol. Biol. Phys.82 ( 2 ), 239 – 246 ( 2012 ).
   PubMedGoogle Scholar
• Hamo C , BloomM, CardinaleDet al. Cancer therapy-related cardiac dysfunction and heart failure. Part 2: prevention, treatment, guidelines and future directions . Circ. Heart Fail.9, e002843 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Hiona A , LeeA, NagendranJet al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function . J. Thorac. Cardiovasc. Surg.142 ( 2 ), 396.e3 – 403.e3 ( 2011 ).
   Web of Science ®Google Scholar
• Tokudome T , MizushigeK, NomaTet al. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry . J. Cardiovasc. Pharmacol.36 ( 3 ), 361 – 368 ( 2000 ).
   PubMed Web of Science ®Google Scholar
• Cardinale D , ColomboA, SandriMet al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin converting enzyme inhibition . Circulation114 ( 23 ), 2474 – 2481 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Gulati G , HeckL, ReeAet al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol . Eur. Heart J.37 ( 21 ), 1671 – 1680 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Bosch X , RoviraM, SitgesMet al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left Ventricular dysfunction with Enalapril and carvedilol in patients submitted to intensive Chemotherapy for the treatment of Malignant hEmopathies) . J. Am. Coll. Cardiol.61 ( 23 ), 2355 – 2362 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Akpek M , OzdogruI, SahinOet al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy . Eur. J. Heart Fail.17 ( 1 ), 81 – 89 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Oliveira P , BjorkJ, SantosMet al. Carvedilol-mediated antioxidant protection against doxorubicin-induced cardiac mitochondrial toxicity . Toxicol. Appl. Pharmacol.200 ( 2 ), 159 – 168 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Elitok A , OzF, CizgiciAet al. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: a prospective randomized controlled study with six-month follow-up . Cardiol. J.21 ( 5 ), 509 – 515 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kaya M , OzkanM, GunebakmazOet al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study . Int. J. Cardiol.167 ( 5 ), 2306 – 2310 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Seicean S , SeiceanA, AlanN, PlanaJ, BuddG, MarwickT . Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure . Circ. Heart Fail.6 ( 3 ), 420 – 426 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Huelsenbeck J , HenningerC, SchadA, LacknerK, KainaB, FritzG . Inhibition of Rac1 signaling by lovastatin protects against anthracycline induced cardiac toxicity . Cell Death Dis.2 ( 8 ), e190 ( 2011 ).
   PubMedGoogle Scholar
• Seicean S , SeiceanA, PlanaJ, BuddG, MarwickT . Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study . J. Am. Coll. Cardiol.60 ( 23 ), 2384 – 2390 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Acar Z , KaleA, TurgutMet al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy . J. Am. Coll. Cardiol.58 ( 9 ), 988 – 989 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Heidenreich P , HancockS, LeeB, MariscalC, SchnittgerI . Asymptomatic cardiac disease following mediastinal irradiation . J. Am. Coll. Cardiol.42 ( 4 ), 743 – 749 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Hahn V , LenihanD, KyB . Cancer therapy-induced cardiotoxicity: basic mechanisms and potential cardioprotective therapies . J. Am. Heart Assoc.3 ( 2 ), e000665 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Hensley M , HagertyK, KewalramaniTet al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemo-therapy and radiation therapy protectants . J. Clin. Oncol.27 ( 1 ), 127 – 145 ( 2009 ).
   PubMed Web of Science ®Google Scholar